Last reviewed · How we verify
NCT05438979
Joint Health Study
NA trial testing Placebo in Effect of Drug in 300 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Auburn University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 300 |
| Start date | 1 July 2022 |
| Primary completion | 30 June 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Placebo
- Calcium Fructoborate
Conditions studied
- Effect of Drug — all drugs for Effect of Drug →
Sponsor
Auburn University
Who can join
Adults 40 to 65, any sex, with Effect of Drug. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Natural dietary health supplements that may improve quality of life by relieving joint discomfort have been of increasing interest. Recent studies have demonstrated promising effects of one such supplement - calcium fructoborate (CFB). Preliminary evidence suggests that CFB may reduce joint discomfort, however, few well-powered studies have been conducted to assess the true effects of this supplement. In this study, conducted virtually, we will examine changes in joint discomfort over a 90 day period. Participants will be randomized to receive either 216mg CFB or placebo (i.e., 216mg microcellulose) to take every day for the study period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05438979
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Effect of Drug
Currently open trials in the same condition.
- NCT07037511 — Effects of Salbutamol in Athletes and Implications for Screening and Sports · NA · recruiting
- NCT06575530 — Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients · Phase 4 · recruiting
- NCT06562816 — Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain · Phase 4 · recruiting
- NCT06479655 — Compare the Efficacy and Outcome Between Fentanyl and Morphine as Analgo-sedation in Mechanically Ventilated Patients · Phase 4 · recruiting
- NCT06000462 — The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes · Phase 4 · active not recruiting
Other Auburn University trials
Trials by the same sponsor.
- NCT05621538 — A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder · NA · recruiting
- NCT06274112 — Using TMS to Understand Neural Processes of Social Motivation · NA · recruiting
- NCT07489105 — Forge AHEAD: Feasibility of Yoga to Improve Cognitive Function · NA · recruiting
- NCT06565637 — Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals With Eating Disorders · Phase 1 · recruiting
- NCT06531863 — Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05438979 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Auburn University
- Last refreshed: 16 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05438979.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing